Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy

Figure 2

The mean changes in BCVA from baseline in IVC, IVR, and IVTA groups over 6 m were as indicated by the ETDRS chart letters. BCVA gradually increased after treatments in all three groups. The increases of BCVA were the most at the end of the first month. At the end of 6 m, the mean BCVA was improved by 25.10 ± 3.73, 26.32 ± 4.06, and 17.16 ± 2.87 letters in IVC, IVR, and IVTA groups, respectively (all values < 0.05).